The chairman of EIPICO – Egypt’s largest pharma company by units –, Dr Ahmed Kelani, outlines the company’s ambitious growth strategy, which includes the construction of the first biological & biosimilar production plant in Egypt. The plant is expected to commence production at the end of 2023 and would become the first of its kind in the Middle East and North Africa (MENA) region. Moreover, Dr Kelani analyses important trends affecting the Egyptian market, and comments on the importance of the country having a local source of APIs.
EIPICO will become the first company in the MENA region to produce biological products starting from the cell line all the way through upstream, downstream, formulation and packing to the final dosage form
